Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions
- PMID: 17611666
Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions
Abstract
Matrix metalloproteinases (MMPs) are proteolytic enzymes that are implicated in multiple stages of cancer progression including invasion and metastasis. MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth factor receptors. By gelatin zymography we verified MMP activity in the pleural effusions of patients with benign and malignant disease. Of these patients, 32 had malignant pleural effusion, consisting of 20 breast cancer, 6 non-small cell lung carcinoma, 4 ovarian carcinoma, and 2 colonic adenocarcinoma, and 10 had benign pleural effusion (5 pleurisy and 5 cirrhosis). Zymography showed the constant presence of a substantial amount of MMP-2 in all samples analyzed, whereas MMP-9 was present to lesser quantities. MMP-2 activity was enhanced in pleural effusions from patients with benign diseases compared with cancer patients. MMP-9 was present in 59% of cancer patients and the lytic activity was enhanced in pleurisy and absent in cirrhosis. Furthermore, we determined the pleural effusion levels of the soluble extracellular domain of HER-2/neu. The levels of HER-2/neu ECD were above the cut-off value in breast cancer patients. No correlation between gelatinolytic activities and high HER-2/neu ECD values was found.
Similar articles
-
Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.Int J Oncol. 2005 May;26(5):1363-8. Int J Oncol. 2005. PMID: 15809729
-
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.Gynecol Oncol. 2001 Aug;82(2):291-8. doi: 10.1006/gyno.2001.6243. Gynecol Oncol. 2001. PMID: 11531282
-
[Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].Wiad Lek. 2007;60(5-6):241-7. Wiad Lek. 2007. PMID: 17966888 Polish.
-
Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.Med Sci Monit. 2009 Feb;15(2):RA32-40. Med Sci Monit. 2009. PMID: 19182722 Review.
-
[Type IV collagenases (MMP-2 and MMP-9) and their substrates--intracellular proteins, hormones, cytokines, chemokines and their receptors].Postepy Biochem. 2007;53(1):37-45. Postepy Biochem. 2007. PMID: 17718386 Review. Polish.
Cited by
-
Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer.Oncol Lett. 2015 Oct;10(4):2527-2532. doi: 10.3892/ol.2015.3558. Epub 2015 Aug 3. Oncol Lett. 2015. PMID: 26622883 Free PMC article.
-
Effect of Glycosaminoglycan Replacement on Markers of Interstitial Cystitis In Vitro.Front Pharmacol. 2020 Dec 3;11:575043. doi: 10.3389/fphar.2020.575043. eCollection 2020. Front Pharmacol. 2020. PMID: 33390947 Free PMC article.
-
Pleural fluid analysis of lung cancer vs benign inflammatory disease patients.Br J Cancer. 2010 Mar 30;102(7):1180-4. doi: 10.1038/sj.bjc.6605607. Epub 2010 Mar 9. Br J Cancer. 2010. PMID: 20216542 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous